Alnylam Pharmaceuticals Inc. Common Stock (ALNY)
Stock · NASDAQ · Health Care
$231.88as of 10/16/2026
Price chart
Active signals
ALNY Signal Track Record
How signals performed across all stocks →What ALNY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.4% | 47% | July 30, 2026 |
| Bollinger Band Breakout | 26 | -2.3% | 42% | September 2, 2026 |
| Bollinger Band Breakdown | 16 | +2.3% | 63% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -2.7% | 50% | April 29, 2025 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2,500
- Website
- www.alnylam.com/
Fundamentals
- 1-day range
- $231.3$237.98
- Market cap
- $28.92B
- P/E (trailing)
- 37.17
- P/E (forward)
- 18.58
- EPS (trailing)
- $5.88
- Dividend yield
- —
- Beta
- 0.37
- Avg. volume
- 1.73M
How Alnylam Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
27 analyst ratings
Alnylam Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- UTHRUnited Therapeutics Corporation Common Stock$533.12▼ 1.55%Market cap $22.62BP/E 17.78$409.07$609.35
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.78 | $533.12 | ▼ 1.55% | $409.07$609.35 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320benzinga · 10/14/2026
- Alnylam vs. Ionis: Here's the Better Bad-News BuyYahoo · 10/10/2026
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyYahoo · 10/9/2026
- Is Vertex Stock Worth More Than Its Competitors?Yahoo · 10/9/2026
- Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% SlideYahoo · 10/9/2026
- EDIT Set to Begin First-in-Human Study in HypercholesterolemiaYahoo · 10/9/2026
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioYahoo · 10/9/2026
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease StudyYahoo · 10/9/2026
- Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value?Yahoo · 10/8/2026
Insider Activity
Insider Actions →- SUPRAN BRYAN · October 2, 2026 · Sale1.8K @ $226.88
- Greenstreet Yvonne · September 19, 2026 · Grant107
- Cravatt Benjamin · June 1, 2026 · Grant4.4K
- David E. I. Pyott · June 1, 2026 · Option Exercise3.8K
- David E. I. Pyott · June 1, 2026 · Sale17 @ $302.65
- David E. I. Pyott · June 1, 2026 · Sale495 @ $300.72
- David E. I. Pyott · June 1, 2026 · Sale1.2K @ $299.87
- David E. I. Pyott · June 1, 2026 · Sale1.2K @ $298.91
- David E. I. Pyott · June 1, 2026 · Sale921 @ $297.71
- Charles Elliott Sigal · May 20, 2026 · Grant671
- Amy W. Schulman · May 20, 2026 · Grant1.8K
- Reitan Colleen F · May 20, 2026 · Grant671
- KELLOGG PETER N · May 20, 2026 · Grant1.4K
- KELLOGG PETER N · May 20, 2026 · Grant671
- HAMBURG MARGARET A · May 20, 2026 · Grant1.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 116.38M
- Total value held
- $36.02B
- Institutional holders
- 776
- Unknown14.58M
- Unknown10.80M
- Unknown10.44M
- Unknown9.47M
- Unknown5.95M
- Unknown5.19M
- Unknown3.32M
- Unknown2.66M
- Unknown2.49M
- Unknown1.99M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.